<DOC>
	<DOCNO>NCT01415609</DOCNO>
	<brief_summary>The purpose study monitor success rate completion rate endoscopic submucosal dissection ( ESD ) gastrointestinal ( GI ) cancer .</brief_summary>
	<brief_title>Endoscopic Submucosal Dissection Registry</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Digestive System Neoplasms</mesh_term>
	<criteria>Patients refer endoscopic treatment advance gastrointestinal ( colorectal , gastric , duodenal , esophagus ) neoplasia , define follow procedure : 1 . Flat dysplastic lesion great 2cm ( IIa IIb Paris classification ) 2 . Flat depress lesion &lt; 2cm size ( llc Paris Classification ) 3 . Ulcerated lesion &lt; 2cm ( Paris type lll ) stag T1N0 endoscopic ultrasound 4 . Upon resection , criterion curative ESD include : Noninvasive neoplasia differentiate carcinoma No lymphovascular invasion Intramucosal cancer minute submucosal cancer &lt; 1 mm invasion ( sm1 ) Negative deep lateral margin . 1 . Use antiplatelet ( e.g . clopidrogel ) anticoagulation ( e.g . Coumadin ) agent withhold least 7 day prior procedure . Aspirin use accept accord American Society Gastrointestinal Endoscopy procedure . 2 . Patients refuse unable consent . 3 . Suboptimal colon prep , solid gastric residual precludes safe lesion resection time endoscopy . 4 . Lesion location segment colon conducive ESD , include significant narrowing , tortuosity and/or extensive diverticular disease , determine endoscopist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Gastrointestinal neoplasia</keyword>
	<keyword>Submucosal resection</keyword>
</DOC>